These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 9881349)

  • 1. [Non-nucleoside reverse transcriptase inhibitors of the human immunodeficiency virus].
    Roca B; Simón E
    Med Clin (Barc); 1998 Nov; 111(17):660-2. PubMed ID: 9881349
    [No Abstract]   [Full Text] [Related]  

  • 2. [Nevirapine (Viramune): a new HIV inhibitor].
    De Wit S; Sternon J; Clumeck N
    Rev Med Brux; 1999 Apr; 20(2):95-9. PubMed ID: 10335104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late breaking news: two additional DHHS guidelines changes. Department of Health and Human Services.
    Bartlett JG
    Hopkins HIV Rep; 1998 May; 10(3):5. PubMed ID: 11365494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine.
    Conway B
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S130-4. PubMed ID: 10860897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What they say about non-nucleoside drugs.
    Posit Aware; 1999; 10(1):35-7. PubMed ID: 11366521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Non-nucleoside reverse transcriptase inhibitor as a fully viable alternative. Strong therapy start without protease inhibitor].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():30-3. PubMed ID: 10863307
    [No Abstract]   [Full Text] [Related]  

  • 7. [Nevirapine--the first non-nucleoside inhibitor of reverse transcriptase in the battle against AIDS].
    Wiese E
    Pharm Unserer Zeit; 1997 Mar; 26(2):99-100. PubMed ID: 9289739
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine.
    Uhlmann EJ; Tebas P; Storch GA; Powderly WG; Lie YS; Whitcomb JM; Hellmann NS; Arens MQ
    J Clin Virol; 2004 Nov; 31(3):198-203. PubMed ID: 15465412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors.
    Tavel JA; Miller KD; Masur H
    Clin Infect Dis; 1999 Mar; 28(3):643-76. PubMed ID: 10194094
    [No Abstract]   [Full Text] [Related]  

  • 10. [Non-nucleoside reverse transcriptase inhibitors].
    Joly V; Yeni P
    Ann Med Interne (Paris); 2000 Jun; 151(4):260-7. PubMed ID: 10922953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
    Krogstad P; Lee S; Johnson G; Stanley K; McNamara J; Moye J; Jackson JB; Aguayo R; Dieudonne A; Khoury M; Mendez H; Nachman S; Wiznia A;
    Clin Infect Dis; 2002 Apr; 34(7):991-1001. PubMed ID: 11880966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of nonnucleoside reverse-transcriptase inhibitors.
    Holtzer CD; Coleman RL
    Am J Health Syst Pharm; 1998 Feb; 55(3):283-7. PubMed ID: 9492261
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
    Benson CA; Deeks SG; Brun SC; Gulick RM; Eron JJ; Kessler HA; Murphy RL; Hicks C; King M; Wheeler D; Feinberg J; Stryker R; Sax PE; Riddler S; Thompson M; Real K; Hsu A; Kempf D; Japour AJ; Sun E
    J Infect Dis; 2002 Mar; 185(5):599-607. PubMed ID: 11865416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resuppression of virus load after interruption in treatment with nevirapine and 2 nucleoside reverse-transcriptase inhibitors.
    Yozviak JL; Doerfler RE; Woodward WC
    Clin Infect Dis; 2002 Feb; 34(4):547-50. PubMed ID: 11797185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New combination medications].
    Agosto M
    Sidahora; 1997; ():43-6. PubMed ID: 11364501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delavirdine (Rescriptor) approved.
    James JS
    AIDS Treat News; 1997 Apr; (No 269):1-3. PubMed ID: 11364252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combined antiretroviral therapy with nevirapine of HIV-infected adults].
    Kravchenko AV
    Ter Arkh; 2004; 76(11):68-71. PubMed ID: 15658542
    [No Abstract]   [Full Text] [Related]  

  • 18. Nevirapine and delavirdine plus protease inhibitors.
    GMHC Treat Issues; 1996 Apr; 10(4):8. PubMed ID: 11363709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.
    Ferrer E; Podzamczer D; Arnedo M; Fumero E; McKenna P; Rinehart A; Pérez JL; Barberá MJ; Pumarola T; Gatell JM; Gudiol F;
    J Infect Dis; 2003 Feb; 187(4):687-90. PubMed ID: 12599088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations on the effectiveness of nevirapine in protease inhibitor-based regimen simplification.
    Martínez E; Gatell JM
    AIDS; 2007 Aug; 21(13):1829-30. PubMed ID: 17690588
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.